Olfactory Response as a Marker for Alzheimer's Disease: Evidence from Perceptual and Frontal Oscillation Coherence Deficit
Mohammad Javad SedghizadehiD, Hadi HojjatiiD, Kiana Ezzatdoost, Hamid K. AghajaniD, Zahra VahabiiD, Heliya Tarighatnia
Abstract
High-frequency oscillations of the frontal cortex are involved in functions of the brain that fuse processed data from different sensory modules or bind them with elements stored in the memory. These oscillations also provide inhibitory connections to neural circuits that perform lower-level processes. Deficit in the performance of these oscillations has been examined as a marker for Alzheimer's disease (AD). Additionally, the neurodegenerative processes associated with AD, such as the deposition of amyloid-beta plaques, do not occur in a spatially homogeneous fashion and progress more prominently in the medial temporal lobe in the early stages of the disease. This region of the brain contains neural circuitry involved in olfactory perception. Several studies have suggested that olfactory deficit can be used as a marker for early diagnosis of AD. A quantitative assessment of the performance of the olfactory system can hence serve as a potential biomarker for Alzheimer's disease, offering a relatively convenient and inexpensive diagnosis method. This study examines the decline in the perception of olfactory stimuli and the deficit in the performance of high-frequency frontal oscillations in response to olfactory stimulation as markers for AD. Two measurement modalities are employed for assessing the olfactory performance: 1) An interactive smell identification test is used to sample the response to a sizable variety of odorants, and 2) Electrophysiological data are collected in an olfactory perception task with a pair of selected odorants in order to assess the connectivity of frontal cortex regions. Statistical analysis methods are used to assess the significance of selected features extracted from the recorded modalities as Alzheimer's biomarkers. Olfactory decline regressed to age in both healthy and Mild AD groups are evaluated, and single- and multi-modal classifiers are also developed. The novel aspects of this study include: 1) Combining EEG response to olfactory stimulation with behavioral assessment of olfactory perception as a marker of AD, 2) Identification of odorants most significantly affected in Mild AD patients, 3) Identification of odorants which are still adequately perceived by Mild AD patients, 4) Analysis of the decline in the spatial coherence of different oscillatory bands in response to olfactory stimulation, and 5) Being the first study to quantitatively assess the performance of olfactory decline due to aging and AD in the Iranian population.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 31
- FWCI
- 0.97
- Field percentile
- top 22%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Short-Lived EEG Synchrony Patterns for Alzheimer's Disease Diagnosis
Bilal Orkan Olcay·bioRxiv·Mar 25, 2026
- Smelling the Risk: Early Olfactory Deficits, Brain Networks, and Blood Markers of Alzheimers Disease Risk in Humanized APOE Mice
Hae Sol Moon, Zay Yar Han, … Alexandra Badea·bioRxiv·Jun 6, 2025
- 18F-FDG-PET Hyperactivity in Alzheimers Disease Cerebellum and Primary Olfactory Cortex
Mark D. Meadowcroft, Carson J. Purnell, … The Alzheimer’s Disease Neuroimaging Initiative·bioRxiv·Jun 5, 2020
- Amyloid-β deposition in basal frontotemporal cortex is associated with selective disruption of temporal mnemonic discrimination
Casey R. Vanderlip, Lisa Taylor, … Jenna N. Adams·Journal of NeurosciencePeer-reviewed·Jan 22, 2025
- Age-Dependent, Odorant-Specific Changes in Olfactory Sensitivity in an Alzheimer's Disease Mouse Model
Yuta Adachi, Kazuki Katori, … Haruki Takeuchi·bioRxiv·May 2, 2025
- Episodic memory ERPs reflect preclinical Alzheimers disease progression
Filipa Raposo Pereira, Maximilien Chaumon, … INSIGHT-preAD study group·bioRxiv·Jul 17, 2026